XML 58 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders’ Equity and Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 28, 2024
Equity [Abstract]  
Schedule of Pre Funded Warrants Activity

The table below summarizes pre-funded warrants activity:

   Pre-funded warrants 
As of December 31, 2022   — 
Issuance of pre-funded warrants   6,000,000 
As of December 30, 2023   6,000,000 
Issuance of pre-funded warrants   4,000,000 
As of December 28, 2024   10,000,000 
Schedule of Non-vested Restricted Stock Activity

 

   Shares  

Weighted Average

Grant Fair Value

   


Fair
Value		     Intrinsic Value  

Non-vested at December 30, 2023

   1,931,767   $1.65    $

3,187,416

     $ 3,921,487  
Granted   4,388,090    1.23    $

5,397,351

       -  
Forfeited   (491,801)   2.17    $

(1,067,209

 )     -  
Vested   (994,445)   1.77    $

(1,760,167

 )     -  

Non-vested at December 28, 2024

   4,833,611   $1.19    $

5,757,391

     $ 6,718,720  
Expected to vest  4,833,611

                      
Schedule of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2024, 2023 and 2022 (no tax benefits were recognized):

 

   2024   2023   2022 
Cost of product revenues  $1,034,422   $1,210,453   $94,634 
Research and development   724,993    861,324    435,842 
Selling, general and administrative   1,575,256    1,803,496    737,229 
Total  $3,334,671   $3,875,273   $1,267,705